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Abstract
Advances of high-throughput technologies have rapidly produced more and more data from DNAs and RNAs to
proteins, especially large volumes of genome-scale data. However, connection of the genomic information to cellular
functions and biological behaviours relies on the development of effective approaches at higher systems level. In
particular, advances in RNA-Seq technology has helped the studies of transcriptome, RNA expressed from the
genome, while systems biology on the other hand provides more comprehensive pictures, from which genes and
proteins actively interact to lead to cellular behaviours and physiological phenotypes. As biological interactions
mediate many biological processes that are essential for cellular function or disease development, it is important to
systematically identify genomic information including genetic mutations from GWAS (genome-wide association
study), differentially expressed genes, bidirectional promoters, intrinsic disordered proteins (IDP) and protein
interactions to gain deep insights into the underlying mechanisms of gene regulations and networks. Furthermore,
bidirectional promoters can co-regulate many biological pathways, where the roles of bidirectional promoters can be
studied systematically for identifying co-regulating genes at interactive network level. Combining information from
different but related studies can ultimately help revealing the landscape of molecular mechanisms underlying
complex diseases such as cancer.
Introductory review:
“On the Origin of Species”, which was published in 1859
authored by Charles Darwin, laid the foundation of theory
of evolution. Modern evolutionary biology has been now
illustrated through genetic variations among individuals.
Today, studies showed that genetic alterations can cause
diseases, yet the driver mutations that cause complex dis-
eases such as cancer remain unclear. Disease-driving geno-
mic alterations can be inferred from comprehensive studies
of genomic data and gene network analysis.
It has been known that many identified mutation-based
drug targets have unwanted side effects of inhibitor treat-
ment that often cause resistance to drugs. Studies of IDP
(intrinsically disordered proteins) showed that due to dif-
ferences in the post-translational circuitry such as the
phosphorylation networks, where phosphorylation sites
are typically within IDP regions of motifs that are dynami-
cally unconserved during evolution. Genetically altered
cells such as cancerous cells often have aggregated muta-
tions in the target kinase. Evolutionary divergence of phos-
phorylation and functional alterations in protein kinases
are likely correlated and evolutionary conserved kinase
substrate interactions in phosphoproteins are more likely
mutated in cancer. Genomic mutation-induced rewiring of
the signalling networks can be prone to complex diseases
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such as cancer. It is important to identify IDP and evolu-
tionary conserved networks that affect diseases for the
identification of underlying disease mechanisms and more
effective drug targets.
Equally important are the identification of bidirectional
promoters and the regulation of genes associated with
mutations or dysregulation in cancer that are enriched
with bidirectional promoters. Those genes such BRCA1,
BRCA2, BARD1, FANCA, FANCF, FANCB, FANCD2,
P53, ERBB2, and CHEK2 work together as a group sharing
regulation by bidirectional promoters and were found pre-
valence in ETS family factors. Identification of biological
roles in bidirectional promoters is essential to our under-
standing of the regulatory mechanisms of bidirectional
promoters and how they can regulate cancer genes. While
common transcription binding factors were found in these
genes, co-expression networks in human cancer can often
be used to infer the underlying disease mechanisms from
bidirectional promoters in combination with gene expres-
sion profile.
Furthermore, advances in high throughput RNA sequen-
cing technologies have generated large volumes of gene
expression data from RNA-Seq in addition to the microar-
ray DNA-chip data. Genomic mutations in disease-causing
genes or structural variations in chromosomes can disturb
signaling pathways that impact the expression of a set of
genes performing certain biological functions. Integrating
differentially expressed genes and pathways can lead to
discovering higher-level disease-associated networks. The
Mid-South Bioinformatics Centre (MBC) and Joint Bioin-
formatics Ph.D. Program of University of Arkansas at
Little Rock and University of Arkansas for Medical
Sciences (UALR-UAMS) are particularly interested in pro-
moting education and research advancement in compre-
hensive translational bioinformatics studies. To promote
synergistic education and research in translational bioin-
formatics, the International Society of Intelligent Biological
Medicine (ISIBM) provided academic sponsorship to the
2014 International Conference on Bioinformatics and
Computational Biology. MBC works with UALR-UAMS
in promoting cutting-edge translational bioinformatics
research.
The 2014 International Conference on Bioinformatics
and Computational Biology received large pool of hun-
dreds of paper submissions. All submitted papers were
peer reviewed by the conference program committee
members (http://www.world-academy-of-science.org/
worldcomp14/ws/conferences/biocomp14/committee) and
invited external experts. Six papers selected to this special
BMC Bioinformatics supplement represent current trends
in the cutting-edge translational bioinformatics research
and were chosen from large submissions by the review
committee chaired by ISIBM President Dr. A. Keith
Dunker (Founding Director and T. K. Li Professor for
Medical Research of Indiana University School of Med-
icine Centre for Computational Biology and Bioinfor-
matics) based on peer-reviews. ISIBM Vice-President
Dr. Hamid R. Arabnia (Editor-in-Chief of Journal of
Supercomputing, Professor of Computer Science at
University of Georgia), Vice-President Dr. Dong Xu
(Editor-in-Chief of International Journal of Functional
Informatics and Personalised Medicine, Associate
Editor-in-Chief of IEEE/ACM Transactions on Computa-
tional Biology and Bioinformatics, James C. Dowell Profes-
sor and Chair of Computer Science Department at
University of Missouri), Secretary-General Dr. Yunlong
Liu (Associate Editor of BMC Genomics, Associate Profes-
sor of Molecular and Medical Genetics and Director of
Bioinformatics Core at Indiana University School of Medi-
cine, Indiana University Purdue University Indianapolis),
Dr. Zhongxue Chen (Associate Editor of BMC Genomics
and Director of Study Design and Data Analysis Consult-
ing Centre of Indiana University at Bloomington),
Dr. Xiang Qin (Assistant Professor of Molecular and
Human Genetics at the Human Genome Sequencing Cen-
tre at Baylor College of Medicine), along with Dr. Weida
Tong (HHS/FDA/NCTR Director of Bioinformatics and
Biostatistics and Professor of Bioinformatics by courtesy at
University of Arkansas at Little Rock, and core faculty of
joint bioinformatics Ph.D. program), and Dr. Youping
Deng (Associate Editor of BMC Research Notes, Associate
Professor of Medicine and Director of Cancer Bioinfor-
matics and Biostatistics of Rush University Medical Centre
in Chicago) also served on the review committee. External
experts were invited to review the submitted papers and
the committee finally select these six significant papers
[1-6] for the BMC Bioinformatics supplement based on
peer-reviews.
In this BMC Bioinformatics supplement, Yang and
Elnitski’s laboratories performed a series of in-depth
investigations and identified bidirectional promoters and
conservations of this type of promoters utilizing ortholo-
gous mapping in human and mouse genomes [1]. They
incorporated data generated by cap analysis gene expres-
sion (CAGE), and validated most of 5’ end of UCSC Gen-
ome Browser annotations that were used in the study.
Their studies of coordinated expression of bidirectional
gene pairs were significant as the conserved bidirectional
promoters in humans have been implicated in complex
diseases such as cancer. While mouse has been used as a
standard model animal for investigating a variety of dis-
eases in humans, compassion with human genes revealed
that bidirectional promoters regulate significant amounts
of genes in mammalian genomes, especially regulate dis-
ease associated genes. Understanding mechanisms of
these promoters based on their functional roles and evo-
lutional patterns can provide valuable resources to
further understanding of gene regulation, transcriptional
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mechanisms and their roles in the disease transformation.
In addition, Yang and Elnitski’s laboratories found that
the gene expression mediated through bidirectional pro-
moters can influence many biological processes such as
histone modification. Furthermore, correlations between
bidirectional promoters and lncRNAs (long non-coding
RNAs) identified by Yang are considered as highly signifi-
cant because such findings can facilitate the identification
of functions of lncRNAs in connection with the regula-
tory roles of bidirectional promoters. This important
work offers deeper insights into the regulatory roles of
bidirectional promoters in connection with lncRNAs in
complex diseases.
Equally impressive is the work of Yang’s laboratory to
systematically investigate TCGA (The Cancer Genome
Atlas) real cancer data. The advent of high-throughput
next-generation sequencing technologies marked the
beginning of a new era for personalized medicine research.
The impact of having an individual genome and persona-
lized genomic data in hands generates high demands of
developing more powerful computational approaches to
handle massive information imbedded in the big data,
which will obviously generate profound effect on how
data-intense biomedical research shall be conducted
toward the improvement of human health and lifesavings.
Yang’s laboratory utilized TCGA RNA-Seq data from
more than 500 kidney renal clear cell carcinoma (KIRC)
patients to investigate genes and pathways that were sig-
nificantly altered in the disease [2]. The laboratory identi-
fied 186 genes with significant differential expressions
between normal and disease samples. They found four-
subtypes of the kidney cancer, which were consistent with
the results of recent publications. In addition, an intelli-
gent SVM (support vector machine) based supervised clas-
sifier was built using the identified differentially expressed
genes to predict unknown samples. The intelligent
machine can effectively distinguish cancer samples from
non-cancer samples with high accuracy. By integrating dif-
ferentially expressed genes with pathway analysis, the
authors revealed several putative pathways disrupted in
the disease. Their results not only confirmed a number of
previously reported disease pathways in literature, but also
identified new roles of pathways in the disease that has
not been well studied yet. Furthermore, based on the dif-
ferentially expressed genes between tumor and normal tis-
sue samples, results from their network analysis suggested
that combining differentially expressed genes, pathways
and networks can infer the upstream regulators, which
can ultimately help identifying disease causal genomic
mutations. The research was a part of the plenary invited
talk entitled “Integrative systems biology approaches to
identify disrupted pathways in disease development”
(http://www.world-academy-of-science.org/worldcomp14/
ws/keynotes/invited_talk_yang ). The integrative methods
presented from Yang’s laboratory demonstrated that com-
bining differentially expressed genes, gene networks and
biological pathways have provided powerful approaches to
further reveal underlying disease mechanisms and effective
drug targets.
Effectively combining information from individual stu-
dies is critical to assess rare variants in GWAS (genome-
wide association study). Chen’s laboratory and collabora-
tors developed a novel statistical approach using the
inverse of the p-value as the shape parameter in the
gamma distribution to more effectively combing p-values
from individual studies [3]. This approach can adaptively
choose the shape parameter of the gamma distribution for
each individual study, since the flexibility in choosing the
parameters allows effectively combing p-values for either
homogenous or heterogeneous individual studies. This is
considered as an improved method to assess the genomic
variants association with diseases, especially to handle the
heterogeneous cases in complex diseases. Chen’s labora-
tory and collaborators demonstrated that the performance
of their new method outperformed existing approaches
when the effects among the studies are more heteroge-
neous. The newly developed approach has been tested
favourably in genome-wide association study.
Intrinsically disordered proteins (IDP) play important
roles in many biological processes that include post-
translational modifications, entropic chain spring-based
restoring forces, flexible linkers, signal transduction, pro-
tein aggregation and coupled folding and binding. Dun-
ker’s laboratory developed new the IDP-Hydropathy scale
using the C-H (charge-hydropathy) plot as the classifier
based on sets of sequences that fold into 3D structure as
compared to collections of sequences that do not fold
[4]. The method provided a measurement of how various
amino acids contribute to protein folding using the prop-
erty of hydropathy. For many years, Dunker’s laboratory
has taken a lead in classifying proteins that either fold
into 3D structures or do not fold into any structure
intrinsically. The paper certainly aided to the advance-
ment of this very important but not widely known field.
Dunker’s laboratory provided a new approach to accu-
rately classify structured and disordered proteins based
on hydropathy using the C-H plot. The authors reported
19 different hydropathy scales including Kyte & Doolittle
scale. They compared the predicting accuracy of the C-H
plot method using different hydropathy scales. They used
support vector machine (SVM) to train the classifier that
discriminates structured proteins from disordered pro-
teins. The weights produced by the SVM are then used
as a new hydropathy scale for the C-H plot. Their new
hydropathy scale was used to boost the predictive power
of the classifier. They concluded that their IDP-Hydropa-
thy would likely be the best scale to use for any type of
algorithm developed to predict protein disorder.
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Lu and Deng’s laboratories and collaborators performed
differentially expressed gene analysis using microarray and
genome-wide expression profile of Type II diabetes (T2D)
[5]. Using blood samples from healthy humans, pre-
diabetic and diabetes patients, they identified 79 differen-
tially expressed genes with fold change larger than 2. They
built a discriminant model using expression levels of 79 dif-
ferential genes in combination with clinical factors that
include age, sex, and race to achieve over 91% accuracy in
diagnosing / predicting status of the T2D (normal people,
pre-diabetic patients and T2D patients). Their Gene
Ontology (GO) analysis revealed a collection of significant
GO term associated with the differential genes. Their
work can provide a combined molecular and pedigree ana-
lytic method that could potentially lead to an effective
screening tool for identifying overall health or illness of
humans and predicting progression of the disease develop-
ment. The pairwise analysis presented in the paper is sig-
nificant and innovative. Combining gene expression,
pathway and network analysis can reveal underlying mole-
cular mechanisms for better preventing, diagnosing and
treating the disease.
United States Foods and Drug Administration (FDA)
has been the leader in drug toxicity studies, Tong’s
laboratory at FDA assessed safety of drugs and the
impact on human health from drug toxicity [6]. Medical
drugs are not natural products and often cause damages
to livers and human health. Unfortunately, toxicity of
many drugs has not been fully studied. The investigators
from United States Foods and Drug Administration and
University of Arkansas at Little Rock fully understand
the importance of a comprehensive assessment of drug
safety and toxicity. They developed a method to system-
atically search the literature and gathered information
together to present the risk of accurate liver failure,
which can be a fatal consequence of certain drugs. This
research opens a new opportunity to comprehensively
identify potential outcomes of certain drugs using acute
liver failure as case studies. Results from the research
can be potentially useful in future personalized geno-
mics and individualized healthcare investigations.
Conclusion
Integrating multi-layer genomic data has helped to reveal
many underlying molecular mechanisms. In particular,
identifying roles of bidirectional promoters with cancer-
related genes using different genome-scale data can sys-
tematically assess genomic mutations and gene expression
that are associated with dysfunctional regulations in cells
and/or malignant transformation, while combining gene
expression and pathway analysis with gene networks using
systems biology approaches can help revealing underlying
disease mechanisms and link pathways to disrupted gene
networks in disease development. The cutting-edge
research presented in this BMC Bioinformatics special
supplement represents the current development of com-
putational approaches in different bioinformatics studies.
Developing approaches to combine the information from
different data helps the advances in translational bioinfor-
matics, which ultimately facilitate revealing the landscape
of complex disease mechanisms.
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